ITMI981671A0 - Derivati ftalazinici inibitori della fosfodisterasi 4 - Google Patents

Derivati ftalazinici inibitori della fosfodisterasi 4

Info

Publication number
ITMI981671A0
ITMI981671A0 IT98MI001671A ITMI981671A ITMI981671A0 IT MI981671 A0 ITMI981671 A0 IT MI981671A0 IT 98MI001671 A IT98MI001671 A IT 98MI001671A IT MI981671 A ITMI981671 A IT MI981671A IT MI981671 A0 ITMI981671 A0 IT MI981671A0
Authority
IT
Italy
Prior art keywords
phosphodisterase
inhibitors
phthalazine derivatives
phthalazine
derivatives
Prior art date
Application number
IT98MI001671A
Other languages
English (en)
Inventor
Gabriele Norcini
Franco Pellacini
Gabriele Morazzoni
Mauro Napoletano
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to IT98MI001671A priority Critical patent/ITMI981671A1/it
Publication of ITMI981671A0 publication Critical patent/ITMI981671A0/it
Priority to AU49116/99A priority patent/AU766076B2/en
Priority to CZ2001240A priority patent/CZ2001240A3/cs
Priority to PCT/EP1999/005068 priority patent/WO2000005219A1/en
Priority to CA002337954A priority patent/CA2337954A1/en
Priority to EP99932894A priority patent/EP1098886A1/en
Priority to JP2000561175A priority patent/JP2002521371A/ja
Priority to EA200100061A priority patent/EA003702B1/ru
Priority to NZ507930A priority patent/NZ507930A/xx
Priority to HU0103349A priority patent/HUP0103349A3/hu
Priority to US09/764,983 priority patent/US6340684B1/en
Priority to IL13949199A priority patent/IL139491A0/xx
Publication of ITMI981671A1 publication Critical patent/ITMI981671A1/it
Priority to ZA200006577A priority patent/ZA200006577B/xx
Priority to US09/987,266 priority patent/US6498160B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/34Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT98MI001671A 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4 ITMI981671A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT98MI001671A ITMI981671A1 (it) 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4
IL13949199A IL139491A0 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase-4 inhibitors
JP2000561175A JP2002521371A (ja) 1998-07-21 1999-07-16 ホスホジエステラーゼ4阻害剤としてのフタラジン誘導体
NZ507930A NZ507930A (en) 1998-07-21 1999-07-16 Phthalazine derivatives as PDE 4 inhibitors for the treatment of respiratory diseases and allergic and inflammatory conditions
PCT/EP1999/005068 WO2000005219A1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
CA002337954A CA2337954A1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
EP99932894A EP1098886A1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
AU49116/99A AU766076B2 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
EA200100061A EA003702B1 (ru) 1998-07-21 1999-07-16 Производные фталазина в качестве ингибиторов фосфодиэстеразы 4
CZ2001240A CZ2001240A3 (cs) 1998-07-21 1999-07-16 Ftalazinové deriváty
HU0103349A HUP0103349A3 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
US09/764,983 US6340684B1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
ZA200006577A ZA200006577B (en) 1998-07-21 2000-11-13 Phthalazine derivatives as phosphodiesterase 4 inhibitors.
US09/987,266 US6498160B2 (en) 1998-07-21 2001-11-14 Phthalazine derivatives as phosphodiesterase 4 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98MI001671A ITMI981671A1 (it) 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4

Publications (2)

Publication Number Publication Date
ITMI981671A0 true ITMI981671A0 (it) 1998-07-21
ITMI981671A1 ITMI981671A1 (it) 2000-01-21

Family

ID=11380475

Family Applications (1)

Application Number Title Priority Date Filing Date
IT98MI001671A ITMI981671A1 (it) 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4

Country Status (13)

Country Link
US (2) US6340684B1 (it)
EP (1) EP1098886A1 (it)
JP (1) JP2002521371A (it)
AU (1) AU766076B2 (it)
CA (1) CA2337954A1 (it)
CZ (1) CZ2001240A3 (it)
EA (1) EA003702B1 (it)
HU (1) HUP0103349A3 (it)
IL (1) IL139491A0 (it)
IT (1) ITMI981671A1 (it)
NZ (1) NZ507930A (it)
WO (1) WO2000005219A1 (it)
ZA (1) ZA200006577B (it)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296984B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
ITMI20000261A1 (it) * 2000-02-16 2001-08-16 Zambon Group Processo per la preparazione di piridiniliden-ftalidi
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
CN1984904A (zh) * 2004-05-08 2007-06-20 神经能质公司 3-芳基-5,6-二取代哒嗪
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JP2008512375A (ja) * 2004-09-03 2008-04-24 メモリ ファーマセチカル コーポレーション 精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ10阻害剤としての4−置換4,6−ジアルコキシ−シンノリン誘導体
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2643044A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009539963A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Parp阻害剤
WO2007144639A1 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
EP2041110A1 (en) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
BRPI0817537B1 (pt) * 2007-10-17 2022-04-05 Kudos Pharmaceuticals Limited 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX2011003740A (es) 2008-10-07 2011-05-02 Astrazeneca Uk Ltd Formulacion farmaceutica - 514.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110015393A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) * 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
GB2063249A (en) 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US6207666B1 (en) * 1995-06-07 2001-03-27 Cell Pathways, Inc. Method for treating a patient having precancerous lesion with 4-phenylphthalazine derivatives
ATE236134T1 (de) 1996-12-18 2003-04-15 Neurogen Corp Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren
IT1296984B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
ITMI981670A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4

Also Published As

Publication number Publication date
JP2002521371A (ja) 2002-07-16
CA2337954A1 (en) 2000-02-03
EP1098886A1 (en) 2001-05-16
ITMI981671A1 (it) 2000-01-21
CZ2001240A3 (cs) 2001-09-12
HUP0103349A2 (hu) 2002-02-28
HUP0103349A3 (en) 2003-01-28
ZA200006577B (en) 2002-04-24
US6498160B2 (en) 2002-12-24
EA200100061A1 (ru) 2001-08-27
WO2000005219A1 (en) 2000-02-03
EA003702B1 (ru) 2003-08-28
US20020058662A1 (en) 2002-05-16
AU766076B2 (en) 2003-10-09
NZ507930A (en) 2002-11-26
US6340684B1 (en) 2002-01-22
AU4911699A (en) 2000-02-14
IL139491A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
ITMI981671A0 (it) Derivati ftalazinici inibitori della fosfodisterasi 4
NO20010193L (no) Tiobenzimidazol-derivater
ITMI981670A0 (it) Derivati ftalazinici inibitori della fosfodiesterasi 4
IT1312558B1 (it) Derivati di alfa-chetoammidi
DE69939689D1 (de) Caspase inhibitoren
DE69934788D1 (de) Biozide benzylbiphenylderivative
NO20010514D0 (no) Aminometylkarboksylsyre-derivater
NO20010046D0 (no) Dolastatin-15-derivater
EE9800219A (xx) Uued 19-nor-pregneeni derivaadid
ATE259810T1 (de) Phenyl-xanthinderivate
IT1296985B1 (it) Derivati benzazinici inibitori della fosfodiesterasi 4
NO20012960D0 (no) Farnesylproteintransferase-inhibitorer
DE69911152D1 (de) Symmetrischer Verstärker
NO20013237L (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
ITMI982216A0 (it) Derivati benzazinici inibitori della fosfodiesterasi 4
DE69939359D1 (de) Verstärker
ITMI982319A0 (it) Derivati triciclici inibitori della fosfodiesterasi 4
DE69837922D1 (de) Il-5 hemmende 6-azauracilderivate
IT1277073B1 (it) Derivati antraciclinici
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ATE233253T1 (de) Chromanderivate
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
DE69930852D1 (de) Prenyltransferase-inhibitoren
IT1273610B (it) Derivati della purporogallina
IT1289621B1 (it) Impiego di derivati della tetraidroisochinolina